728 related articles for article (PubMed ID: 23006951)
1. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
Foyil KV; Bartlett NL
Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
[TBL] [Abstract][Full Text] [Related]
2. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
3. Brentuximab vedotin in anaplastic large cell lymphoma.
Skarbnik AP; Smith MR
Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
[TBL] [Abstract][Full Text] [Related]
4. Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL.
Liu W; Wu J; Ming X; Zhang Q; Zhou D; Zheng R; Zhou M; Shang Z; Chen L; Zhu X; Xiao Y
Front Immunol; 2024; 15():1346001. PubMed ID: 38375471
[TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.
Agrusa JE; Egress ER; Lowe EJ
Front Immunol; 2023; 14():1203471. PubMed ID: 37275877
[TBL] [Abstract][Full Text] [Related]
6. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
7. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
8. [Brentuximab vedotin: new treatment for CD30+ lymphomas].
Terriou L; Bonnet S; Debarri H; Demarquette H; Morschhauser F
Bull Cancer; 2013; 100(7-8):775-9. PubMed ID: 23831822
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
Pro B; Advani R; Brice P; Bartlett NL; Rosenblatt JD; Illidge T; Matous J; Ramchandren R; Fanale M; Connors JM; Yang Y; Sievers EL; Kennedy DA; Shustov A
J Clin Oncol; 2012 Jun; 30(18):2190-6. PubMed ID: 22614995
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
Minich SS
Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
[TBL] [Abstract][Full Text] [Related]
11. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding.
Al-Rohil RN; Torres-Cabala CA; Patel A; Tetzlaff MT; Ivan D; Nagarajan P; Curry JL; Miranda RN; Duvic M; Prieto VG; Aung PP
J Cutan Pathol; 2016 Dec; 43(12):1161-1166. PubMed ID: 27531242
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab vedotin (SGN-35) in a 3-year-old child with relapsed systemic anaplastic large cell lymphoma.
Mikles B; Levine J; Gindin T; Bhagat G; Satwani P
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e85-7. PubMed ID: 23588340
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
14. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.
Gualberto A
Expert Opin Investig Drugs; 2012 Feb; 21(2):205-16. PubMed ID: 22127011
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin in systemic T-cell lymphoma.
Oki Y; Younes A
Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A; Soma L
Cancer Treat Res; 2019; 176():127-144. PubMed ID: 30596216
[TBL] [Abstract][Full Text] [Related]
18. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.
Boi M; Zucca E; Inghirami G; Bertoni F
Br J Haematol; 2015 Mar; 168(6):771-83. PubMed ID: 25559471
[TBL] [Abstract][Full Text] [Related]
19. Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.
Haddley K
Drugs Today (Barc); 2012 Apr; 48(4):259-70. PubMed ID: 22536568
[TBL] [Abstract][Full Text] [Related]
20. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
